Skip to content
Retatrutide Guide

Reference asset · April 2026

Retatrutide molecular structure, annotated

Retatrutide is a synthetic peptide. This page breaks the molecule into its functional regions — what each part does biologically, and why each part exists.

Editorially reviewed April 2026Updated April 28, 2026Independent medical reviewer onboarding

Annotated peptide structure

Retatrutide is a 39-residue peptide with a fatty-acid tail

Annotated diagram of the retatrutide peptideN-TERMINUSC-TERMINUSReceptor-binding N-terminusResidues 1–14Helical coreResidues 15–30C-terminal tailResidues 31–39KC20 fatty-acid tailBinds albumin → multi-day half-life → once-weekly dosing
  • Receptor-binding N-terminus· Residues 1–14

    The N-terminal region binds the orthosteric pocket of the GLP-1, GIP, and glucagon receptors. Small substitutions in this region tune relative receptor potency.

  • Helical core· Residues 15–30

    An alpha-helical core stabilizes the peptide's three-dimensional shape and contributes to receptor selectivity. DPP-4-resistant residues prevent the rapid breakdown that limits native GLP-1.

  • C-terminal tail· Residues 31–39

    The C-terminal tail anchors the peptide and presents the lysine residue at position 20 (numbering varies by reference) bearing the fatty-acid side chain that drives albumin binding and the multi-day half-life.

Schematic representation. Retatrutide's reported amino-acid sequence is engineered for balanced agonism at the GLP-1, GIP, and glucagon receptors and DPP-4 resistance. Exact residue numbering varies by reference; the regions above are functional, not position-exact.

Why retatrutide looks the way it does

Retatrutide's sequence is built on the glucagon-family peptide backbone — the same scaffolding that underlies the native hormones it mimics. Three engineering choices turn that scaffold into a once-weekly drug.

1. Tuned receptor selectivity

Native glucagon, GLP-1, and GIP each have distinct sequences that bind their respective receptors. Retatrutide is a hybrid: certain residues are kept from glucagon, others from GLP-1, and others again from GIP. The mix is tuned so that the molecule is a meaningful agonist at all three receptors but not equipotent — Lilly biased the activity toward weight loss while keeping glucose handling under control. [1]

2. DPP-4 resistance

Native GLP-1 lasts only a couple of minutes in the bloodstream because the enzyme DPP-4 cleaves it almost immediately. Retatrutide's sequence includes substitutions at positions DPP-4 normally targets, which makes the molecule essentially DPP-4-resistant. Without this, no peptide-based GLP-1 drug would be practical.

3. The fatty-acid tail

A long fatty-acid (C20) chain is attached to a lysine residue partway along the peptide. The chain doesn't bind the target receptors directly. Instead, it binds non-covalently to albumin, the most abundant protein in blood. Albumin binding dramatically slows renal clearance, pushing the half-life from minutes to days — enough to support once-weekly dosing. The same engineering trick is used in semaglutide and tirzepatide.

What this means at the patient scale

The molecule doesn't look very different from semaglutide or tirzepatide at this resolution — it's the same general size, the same general shape, the same albumin-binding strategy. The differences are in whichresidues sit where, and that small shift is what produces a meaningful agonist at three receptors instead of one or two.

This is also why generic or compounded retatrutide is hard. A "research peptide" vendor cannot meaningfully validate that their peptide is the same molecule — sequence, fatty-acid attachment, and receptor selectivity are all critical to the drug's actual pharmacology, and none can be confirmed at home.

Sources

Primary sources cited on this page

  1. Coskun T, et al.. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022. Source ↗
  2. PubChem. Retatrutide (LY3437943) chemical record. NCBI. 2026. Source ↗